RxDoctor Payments Data

Rashida Abbas, MD

Cardiovascular Disease · Huntsville, ALNPI 1811044605

Payments from drug & device makers

What this record shows

13 manufacturers reported payments, led by Abbott at 36.1% of the total. 2025 is the largest year on record at $1,370, 3.3 times the $411 reported in 2019.

$3,613in general payments, 2019–2025

Across 79 payments — averaging $45.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Edwards Lifesciences$1K
  • Boston Scientific$269
  • Johnson & Johnson$252
  • Novartis$204
  • Pfizer$108
  • plus $262 from 7 others
$41,408in research payments, 2019–2025

Across 6 payments — averaging $6901.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ionis Pharmaceuticals, Inc.$41K

What the payments were for

  • Travel & lodging$1,86152%
  • Food & beverage$1,75248%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,613 in reported general payments places this provider in the 55th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$114,431
Medicare patients
693
Services billed
2,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban489$492,659
EntrestoSacubitril/Valsartan179$213,421
Repatha SureclickEvolocumab160$143,810
XareltoRivaroxaban123$130,057
FarxigaDapagliflozin Propanediol94$65,135
JardianceEmpagliflozin36$38,333
MultaqDronedarone Hcl17$26,135
Ranolazine ErRanolazine130$13,645
Praluent PenAlirocumab11$10,280
Metoprolol Succinate433$7,384
Rosuvastatin Calcium275$6,697
Atorvastatin Calcium413$6,100
Ezetimibe124$4,072
Flecainide Acetate93$3,923
Dabigatran EtexilateDabigatran Etexilate Mesylate15$3,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$108$492,659489 claims
NovartisEntresto$204$213,421179 claims
Johnson & JohnsonXarelto$252$130,057123 claims
AstraZenecaFarxiga$15$65,13594 claims
Sanofi-aventis U.S. LLCMultaq$12$26,13517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →